The NIH reports that 70% of medicines given to children have only been studied in adults; therefore, most drugs used to treat diseases in children are used off-label — without an adequate understanding of the appropriate dose, safety, or efficacy. Off-label prescribing has become the treatment of choice because of the lack of clinical trials in the pediatric population.
Ensuring Children’s Voices are Heard in Clinical Trials
World Children’s Day at PRA Health Sciences recognizes children’s rights to safe and effective treatments. This year, the teams from PRA’s Center for…
RACE Act is significantly changing clinical development. Are you ready?
Our team is here to help you navigate this historic transition in our industry.
Michael Durwin, Director of Social Intelligence and Communities
We measure our HQ with actions, experiences, and intentions. Nowhere is that more evident that in the stories of our subject matter experts. We want…